A Sjogrens trial of ianalumab (in Phase III) announced reaching primary endpoints. Ianalumab is a B-cell depletion and BAFF-R inhibition treatment. Ianalumab has the potential to become the first and only targeted treatment for Sjogrens, once its approved. www.novartis.com/news/media-r...
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
novartis.com